within Pharmacolibrary.Drugs.ATC.H;

model H01CB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.12666666666666665,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.0294,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Pasireotide is a synthetic somatostatin analog, used primarily in the treatment of Cushing’s disease and acromegaly when surgery is not effective or feasible. It acts by binding to multiple somatostatin receptor subtypes to inhibit ACTH secretion. It is an approved drug and used today, mainly for endocrine disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers (both sexes) after subcutaneous administration of pasireotide in clinical studies.</p><h4>References</h4><ol><li><p>Nedelman, J, et al., &amp; Zhou, J (2018). Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing&#x27;s Disease Patients. <i>Clinical pharmacokinetics</i> 57(7) 855–866. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0600-y&quot;>10.1007/s40262-017-0600-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29032486/&quot;>https://pubmed.ncbi.nlm.nih.gov/29032486</a></p></li><li><p>Johnsson, M, et al., &amp; Tiberg, F (2024). Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide. <i>Endocrine</i> 84(3) 1125–1134. DOI:<a href=&quot;https://doi.org/10.1007/s12020-024-03741-3&quot;>10.1007/s12020-024-03741-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38421556/&quot;>https://pubmed.ncbi.nlm.nih.gov/38421556</a></p></li><li><p>Chen, X, et al., &amp; Hu, P (2014). Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. <i>Clinical therapeutics</i> 36(8) 1196–1210. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2014.06.006&quot;>10.1016/j.clinthera.2014.06.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25012727/&quot;>https://pubmed.ncbi.nlm.nih.gov/25012727</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01CB05;
